Asahi Intecc annual net profit rose 151.8%
Asahi Intecc expects medical-component sales to grow as demand for cardiovascular catheter components continues to expand.
Asahi Intecc Co., Ltd. (TSE-7747) reported profit attributable to owners of the parent of 32,075 million yen for the year ended June 30, 2026, up 151.8% from a year earlier, as ordinary profit increased and impairment losses fell substantially.
Asahi Intecc's medical business recorded sales of 126,798 million yen, an increase of 17.6% from the previous fiscal year.
Profit at Asahi Intecc's medical business reached 46,190 million yen, rising 38.1% from the previous fiscal year.
Domestic sales in Asahi Intecc's medical business increased because of strong sales of purchased peripheral vascular products within its non-cardiovascular business.
Overseas sales in Asahi Intecc's medical business increased across both cardiovascular and non-cardiovascular products, with exchange-rate movements also contributing to the growth.
Asahi Intecc's cardiovascular sales increased in every region, with PCI guidewires and penetration catheters accounting for the main areas of growth.
Asahi Intecc's non-cardiovascular sales increased as abdominal and peripheral vascular products grew in every region and cerebrovascular products also recorded growth across overseas markets as a whole.
Asahi Intecc's device business posted sales of 18,620 million yen, an increase of 52.1% compared with the previous fiscal year.
Profit at Asahi Intecc's device business rose 83.5% to 8,485 million yen, with the increase attributable to higher sales to external customers.
Asahi Intecc's medical-component sales increased through more business supplying cardiovascular diagnostic catheter components to American companies and cardiovascular ultrasound catheter components to Asia, as well as the consolidation of Nitta Mold.
Asahi Intecc's industrial-component sales increased through growth in leisure-related business in overseas markets and the addition of Nitta Mold to the consolidated group.
Asahi Intecc expects medical-component sales to increase as demand continues to expand for components used in cardiovascular diagnostic and treatment catheters, particularly those supplied to major medical-device manufacturers in the United States.
Asahi Intecc expects industrial-component sales to rise as strong leisure-related and office-equipment business supports growth despite an anticipated decline in business supplying the automotive market.
Asahi Intecc expects overseas sales of its own-brand products to increase in both cardiovascular and non-cardiovascular applications through measures that include continuing efforts to expand market share across all overseas regions.
Asahi Intecc aims to sustain cardiovascular sales growth, including through market-share gains, particularly in China, where the number of procedures was increasing markedly.
Asahi Intecc expects sales of its own-brand abdominal, peripheral vascular and cerebrovascular products within the non-cardiovascular business to increase in every region.
Asahi Intecc expects sales from its original-equipment manufacturing business to grow mainly through overseas business, including increased supplies of peripheral artery atherectomy catheters to the United States.
Asahi Intecc expects its gross profit margin to rise through productivity improvements and other factors, despite pressure from higher material costs and other expenses.